The HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
What they do
Evozyne engineers novel proteins by combining deep learning with a high-throughput closed-loop synthesis platform. The company serves the pharmaceutical and agricultural industries, designing enzymes and proteins with targeted functions for therapeutics, sustainability, and industrial chemistry.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Protein design
- Product type
- Platform software
- Stage
- Series B
- Headquarters
- Chicago, USA
- Region
- North America
- Founded
- 2020
- Total funding
- $139M raised
Notable investors: Fidelity Management & Research, OrbiMed, Paragon Biosciences, Valor Equity Partners.
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
Bypassing Carrier Suppression: The 31-Valent Conjugate Architecture Reshaping Pneumococcal Vaccinology
Dr. Dereck Mush, MD, MBA
AI is moving upstream, from molecule design into disease target identification itself
Dr. Dereck Mush, MD, MBA
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBA